['hypercholesterolemia']
['alirocumab', 'placebo', 'atorvastatin', 'non-statin lipid-modifying therapy']

        Inclusion criteria :

        Participants with hypercholesterolemia (heFH or non-FH) receiving non statin LMTs or the
        lowest strength of statin.

        Exclusion criteria:

          -  LDL-C <100 mg/dL (<2.59 mmol/L) at the screening visit (Week -3) in participants with
             heFH or in participants with non-FH who have a history of documented coronary heart
             disease.

          -  LDL-C <120 mg/dL (<3.10 mmol/L) at the screening visit (Week -3) in participants with
             non-FH participants who had a history of documented diseases or other risk factors
             classified as primary prevention category III as defined in JAS Guidelines for
             Prevention of Atherosclerotic Cardiovascular Diseases 2012.

          -  Not on a stable dose of LMT (including diet therapy alone) in the run-in period or the
             screening period.

          -  Fasting serum TGs >400 mg/dL (>4.52 mmol/L) at the screening period.

          -  Systolic blood pressure (BP) >160 mmHg or diastolic BP >100 mmHg at the run-in visit
             (Week -7) or the screening visit (Week -3) or the randomization visit (Week 0).

        The above information was not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
      